Abstracts Archive - Page 1275 of 2425 - ACR Meeting Abstracts

Abstract Number: 1042 • 2017 ACR/ARHP Annual Meeting
Remote Management of Osteoporosis Screening and Treatment in US Veterans Using a Bone Health Team: A Cost-Effectiveness Analysis
Karla L. Miller¹, Jordan King², Phillip Lawrence³, Richard Nelson⁴, Joanne Lafleur⁵, Grant Cannon⁶ and Scott Nelson⁷, ¹Internal Medicine, Veterans Affairs Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, ²Clinical Pharmacy Specialist, Research, Kaiser Permanente Colorado, Aurora, CO, ³Salt Lake City VA Medical Center and Roseman University of Health Sciences, Salt Lake City, UT, ⁴Epidemiology, Veterans Affairs Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, ⁵University of Utah Department of Pharmacotherapy and Salt Lake City VA Medical Center, Salt Lake City, UT, ⁶Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁷Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN
Remote Management of Osteoporosis Screening and Treatment in US Veterans using a Bone Health Team: A Cost-effectiveness Analysis Background/Purpose: To evaluate the cost effectiveness of…
Abstract Number: 1043 • 2017 ACR/ARHP Annual Meeting
Comparison of the Costs for Hyaluronic Acid and Total Knee Arthroplasty in the Treatment of OA for the Blue Cross/Blue Shield Patient Population
Kevin Ong¹, Faizan Niazi², Edmund Lau³, Peter Shaw² and Steven Kurtz¹, ¹Exponent, Inc., Philadelphia, PA, ²Ferring Pharmaceuticals, Inc., Parsippany, NJ, ³Exponent, Inc., Menlo Park, CA
Background/Purpose: Previous HA studies have focused on the Medicare population, but less is known of the treatment patterns and cost of HA relative to knee…
Abstract Number: 1044 • 2017 ACR/ARHP Annual Meeting
Medical Care Costs Associated with Rheumatoid Arthritis in the US: A Meta-Analysis
Andrew Hresko¹, Tzu-Chieh Lin² and Daniel H. Solomon³, ¹Tufts Medical School, Boston, MA, ²Health Outcomes, Amgen, Thousand Oaks, CA, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) is a morbid, mortal, and costly condition without a cure. Treatments for RA have expanded over the last two decades…
Abstract Number: 1045 • 2017 ACR/ARHP Annual Meeting
The Potential Value of a Shared Decision-Making Intervention for Choices Regarding Triple Therapy in Rheumatoid Arthritis
Nick Bansback¹, Tima Mohammadi², Aslam Anis³, James R. O'Dell⁴ and Glen Hazlewood⁵, ¹School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada, ²Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada, ³University of British Columbia, School of Population and Public Health, Vancouver, BC, Canada, ⁴Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ⁵Division of Rheumatology, University of Calgary, Calgary, AB, Canada
Background/Purpose: Previous studies have shown that using Triple Therapy (a combination of 3 generic drugs) prior to a biologic, is the most cost-effective strategy for…
Abstract Number: 1046 • 2017 ACR/ARHP Annual Meeting
Biological and Targeted Synthetic Dmards’ Prior Authorization Time Is Significantly Reduced with Pharmacy Presence in the Rheumatology Clinic
Wendy Ramey¹, Kristine M. Lohr², Matt Zeltner¹, Haley Herrell Postonl¹, Andrew Johannemann¹, Aric D. Schadler¹ and Aleksander Lenert³, ¹University of Kentucky, Lexington, KY, ²Rheumatology, University of Kentucky, Lexington, KY, ³Internal Medicine, Div. of Rheumatology, University of Kentucky, Lexington, KY
Background/Purpose: Treatment with biological DMARDs (bDMARD) and targeted synthetic DMARDs (tsDMARD) has led to improved outcomes for chronic rheumatic diseases. Current treat-to-target (T2T) strategy relies…
Abstract Number: 1047 • 2017 ACR/ARHP Annual Meeting
Cost-Effectiveness of Drug-Level Guided Adalimumab Dosing
Zara Izadi¹, Gabriela Schmajuk², Milena Gianfrancesco³, Laura Trupin⁴, Kashif Jafri⁵, Jinoos Yazdany⁴ and Dhruv Kazi⁶, ¹Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, ²San Francisco VA Medical Center, University of California San Francisco, San Francisco, CA, ³Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁴Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, ⁵University of California, San Francisco, San Francisco, CA, ⁶Department of Medicine, University of California, San Francisco, Zuckerberg San Francisco General Hospital, San Francisco, CA
Background/Purpose: Adalimumab (ADA) induces and maintains clinical remission in patients with rheumatoid arthritis (RA) and Crohn’s disease (CD) but is an expensive drug. Drug-level and…
Abstract Number: 1048 • 2017 ACR/ARHP Annual Meeting
Efficacy of Educating Visiting Pharmacists Regarding Drug Administration for Patients with Rheumatoid Arthritis Who Poorly Adhere to Treatment Regimens
Masatoshi Hayashi¹, Hiroyuki Matsubara², Kei Funamura¹, Masataka Maeda¹ and Toshihisa Kanamono¹, ¹Rheumatology, Nagano Red Cross Hospital, Nagano, Japan, ²Orthopaedics, Hekinan municipal hospital, Hekinann, Japan
Background/Purpose: Patients with rheumatoid arthritis (RA) need to take lifelong oral or injectable medication to alleviate their symptoms and prevent disease progression. However, some patients…
Abstract Number: 1049 • 2017 ACR/ARHP Annual Meeting
Heart Rate Variability Testing with Autonomic Nervous System Optimization: Could It Change the Course of Spending for Rheumatoid Arthritis Patients in the U.S.? an Exploratory Minimal Model Analysis
Marita Zimmermann¹, Elisabeth Vodicka², Andrew J Holman^3,4,5 and Louis P Garrison², ¹Constants in Global Health, University of Washington, Seattle, WA, ²Consultants in Global Health, University of Washington, Seattle, WA, ³Rheumatology, Pacific Rheumatology Associates Inc PS, Seattle, WA, ⁴Inmedix, Normandy Park, WA, ⁵Pacific Rheumatology Reseach, Seattle, WA
Background/Purpose: Autonomic nervous system (ANS) testing with heart rate variability (HRV) has been shown to predict 52-week anti-TNF therapeutic outcomes in rheumatoid arthritis (RA).1 HRV…
Abstract Number: 1050 • 2017 ACR/ARHP Annual Meeting
Prevalence and Predictors of Knee Replacement Overuse and Underuse in the US
Hassan Ghomrawi¹, Alvin Mushlin², Raymond Kang³, Samprit Banerjee², Jasvinder A. Singh⁴, Leena Sharma⁵, Tuhina Neogi⁶, Michael C. Nevitt⁷ and Daniel Riddle⁸, ¹Surgery and Pediatrics/Center for Healthcare Studies, Feinberg School of Medicine of Northwestern University, Chicago, IL, ²Healthcare Policy and Research, Weill Cornell Medical College, New York, NY, ³Center for Healthcare Studies, Feinberg School of Medicine of Northwestern University, Chicago, IL, ⁴Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ⁷Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, ⁸Virginia Commonwealth University, Richmond, VA
Background/Purpose: The elective nature of knee replacement (KR) creates difficult decisions and the potential for both overuse and underuse. We examined the temporal relationship between…
Abstract Number: 1051 • 2017 ACR/ARHP Annual Meeting
Telemedicine for Rheumatoid Arthritis in the Alaska Native Population
Elizabeth Ferucci¹, Tammy Choromanski¹, Gretchen Day² and Sarah Freeman³, ¹Division of Community Health Services, Alaska Native Tribal Health Consortium, Anchorage, AK, ²Clinical and Research Services, Alaska Native Tribal Health Consortium, Anchorage, AK, ³Alaska Native Tribal Health Consortium, Anchorage, AK
Background/Purpose: Access to a rheumatologist and frequent monitoring of disease activity in rheumatoid arthritis (RA) are associated with higher quality of care and improved outcomes.…
Abstract Number: 1052 • 2017 ACR/ARHP Annual Meeting
Systematic Review of Modelling Approaches and Quality for the Cost Effectiveness of sequential Targeted Therapy in Patients with Rheumatoid Arthritis That Show an Inadequate Response to at Least One Tumor Necrosis Factor Alpha Inhibitor
Aliza Matusevich¹, Maria Suarez-Almazor¹, Scott B. Cantor² and Maria A. Lopez-Olivo¹, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ²Department of Health Services Research, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX
Background/Purpose: Results from cost-effectiveness analysis (CEAs) comparing treatment options for patients with rheumatoid arthritis (RA) who have an inadequate response to an initial tumor necrosis…
Abstract Number: 1053 • 2017 ACR/ARHP Annual Meeting
Impact of Step Therapy Protocols on North Carolina Rheumatologists’ Job Satisfaction and the Quality of Care Received By Their Patients with Rheumatoid Arthritis
Victoria Hamby¹, Amanda Nelson², Antonia Bennett¹, Leigh F. Callahan³ and Stacie Dusetzina⁴, ¹Gillings School of Global Public Health, Department of Health Policy and Management, University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Division of Rheumatology, Allergy, and Immunology and Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, ³Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁴Eshelman School of Pharmacy and Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Early diagnosis and treatment of rheumatoid arthritis (RA) is crucial in minimizing disease damage. Step-therapy, a form of prior authorization used by payers to…
Abstract Number: 1054 • 2017 ACR/ARHP Annual Meeting
Healthcare Utilization Profiles in Rheumatoid Arthritis – a Cluster Analysis
Nina Mars^1,2, Anne M Kerola^2,3, Markku J Kauppi^4,5, Matti Pirinen¹, Outi Elonheimo⁶ and Tuulikki Sokka-Isler⁷, ¹Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland, ²University of Helsinki, Helsinki, Finland, ³Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland, ⁴School of Medicine, University of Tampere, Tampere, Finland, ⁵Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland, ⁶FCG Finnish Consulting Group Ltd., Helsinki, Finland, ⁷Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland
Background/Purpose: Utilization patterns in rheumatoid arthritis (RA) are complex. For targeted interventions, patients with special healthcare needs should be recognized. Our aim was to explore…
Abstract Number: 1055 • 2017 ACR/ARHP Annual Meeting
A Combination of Self-Reported Symptoms and ACPA Testing Can Identify Individuals with Previously Undiagnosed Inflammatory Arthritis in a Health-Fair Setting
Elizabeth A. Bemis¹, Nicholas Ellinwood², Kaylynn Aiona³, Christopher C. Striebich⁴ and Kevin D. Deane⁵, ¹Epidemiology, Colorado School of Public Health, Aurora, CO, ²Pharmacology and Toxicology Graduate Group, University of California Davis, Davis, CA, ³Denver Health and Hospitals and Colorado School of Public Health, Denver, CO, ⁴Division of Rhuematology, University of Colorado School of Medicine, Aurora, CO, ⁵Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Early identification and treatment of inflammatory arthritis (IA) and in particular rheumatoid arthritis (RA) can lead to improved outcomes. However, there are often delays…
Abstract Number: 1056 • 2017 ACR/ARHP Annual Meeting
Evolution of Health Care Consumption in the Knee and Hip Osteoarthritis Long Term Assessment Cohort, a French Population Based Cohort of Symptomatic Knee and/or Hip OA Patients
Anne-Christine Rat^1,2,3, Jean-Hugues Salmon⁴, Willy Ngueyon Sime⁵, Maud Wieczorek⁶, Alain Saraux⁷, Claudine Gard⁸, Francis Guillemin⁹ and Bruno Fautrel¹⁰, ¹Inserm, CIC-1433 Epidémiologie Clinique, Vandoeuvre-lès-Nancy, France, ²Rheumatology Department, CHRU Nancy, Vandoeuvre-lès-Nancy, France, ³Université de Lorraine, EA4360, APEMAC, Nancy, France, ⁴Rheumatology, Rheumatology Department CHU Teaching Hospital Reims, Reims, France, ⁵CIC 1433 Epidémiologie clinique, Inserm, Nancy, France, ⁶Université de Lorraine EA 4360 APEMAC, Nancy, France, ⁷Rheumatology Department, Rheumatology Department, CHU de la Cavale Blanche, Brest, France, Brest Cedex, France, ⁸Pitié Salpetrière hospital, Paris, France, ⁹CHRU Nancy, Clinical Epidemiology and Evaluation, Université de Lorraine, Paris Descartes University, APEMAC, EA 4360, Nancy, France, ¹⁰UPMC University Paris 06, Pitié-Salpétrière Hospital, Paris, France
- Background/Purpose: in hip and knee OA, one of the leading causes of global disability, recent population-based data of health care practices and utilization are scarce.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].